The UTHR chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the UTHR chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The UTHR stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View UTHR Detailed Price Forecast - CNN Money||View UTHR Detailed Summary - Google Finance|
|View UTHR Detailed Summary - Yahoo! Finance||View UTHR Stock Research & Analysis - Zacks.com|
|View UTHR Trends & Analysis - Trade-Ideas||View UTHR Major Holders - Barrons|
|View UTHR Call Transcripts - NASDAQ||View UTHR Breaking News & Analysis - Seeking Alpha|
|View UTHR Annual Report - CompanySpotlight.com||View UTHR OTC Short Report - OTCShortReport.com|
|View UTHR Fundamentals - TradeKing||View UTHR SEC Filings - Bar Chart|
|View Historical Prices for UTHR - The WSJ||View Performance/Total Return for UTHR - Morningstar|
|View the Analyst Estimates for UTHR - MarketWatch||View the Earnings History for UTHR - CNBC|
|View the UTHR Earnings - StockMarketWatch||View UTHR Buy or Sell Recommendations - MacroAxis|
|View the UTHR Bullish Patterns - American Bulls||View UTHR Short Pain Metrics - ShortPainBot.com|
|View UTHR Stock Mentions - StockTwits||View UTHR Stock Mentions - PennyStockTweets|
|View UTHR Stock Mentions - Twitter||View UTHR Investment Forum News - Investor Hub|
|View UTHR Stock Mentions - Yahoo! Message Board||View UTHR Stock Mentions - Seeking Alpha|
|View Insider Transactions for UTHR - SECform4.com||View Insider Transactions for UTHR - Insider Cow|
|View UTHR Major Holdings Summary - CNBC||View Insider Disclosure for UTHR - OTC Markets|
|View Insider Transactions for UTHR - Yahoo! Finance||View Institutional Holdings for UTHR - NASDAQ|
|View UTHR Stock Insight & Charts - FinViz.com||View UTHR Investment Charts - StockCharts.com|
|View UTHR Stock Overview & Charts - BarChart||View UTHR User Generated Charts - Trading View|
CollPlant (CLGN) (CLGN.TA) and United Therapeutics Corporation (UTHR) today announced that they have entered into a license, development and commercialization agreement for 3D bioprinted lung transplants. Under terms of the agreement, CollPlant granted United Therapeutics, through its wholly owned organ manufacturing and transplantation-focused subsidiary Lung Biotechnology PBC, an exclusive license to its technology for the production and use of rhCollagen-based BioInk for 3D bioprinted lung transplants throughout the universe. CollPlant will manufacture and supply BioInk for a few years to meet development process demand, and will provide technical support to United Therapeutics as it establishes a U.S. facility for the manufacture of CollPlant's rhCollagen and BioInk.
United Therapeutics (UTHR) Q3 Earnings Preview: What's in the Cards?
Posted on Wednesday October 17, 2018
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why MannKind Corp. Soared 16.4% Tuesday
Posted on Tuesday October 16, 2018
The company has completed its planned transaction with United Therapeutics.
United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement
Posted on Tuesday October 16, 2018
United Therapeutics Corporation (UTHR) and MannKind Corporation (MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.